Site Overlay




Nuclear Medicine and Biology (2020). “Preclinical evaluation of [18F] D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain.”
Nuclear Medicine and Biology (2019). “Optimization of solid-phase extraction (SPE) in the preparation of [18F] D3FSP: A new PET imaging agent for mapping Aβ plaques.”
Nuclear Medicine and Biology (2019). “VMAT2 imaging agent, D6-[18F] FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization.”
Nuclear Medicine and Biology (2018). “Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent.
Nuclear medicine and biology  (2018). “Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain.”

Nuclear medicine and biology  (2018). “Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent.”

 Journal of Nuclear Medicine (2017). “Metabolic imaging of glutamine in cancer.”
Journal of the American Chemical Society (2011). “Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors.”
Molecular imaging and biology (2019). “[68 Ga] Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68 Ga] Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.”

Nuclear Medicine and Biology (2018). “Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor.”

Copyright © 2020 北京宾派生物技术公司. All Rights Reserved.